Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 1
1977 1
1978 2
1979 1
1981 1
1982 4
1983 2
1984 1
1985 1
1986 1
1987 1
1989 1
1991 1
1992 2
1993 2
1994 4
1995 4
1996 2
1997 4
1998 3
1999 2
2000 4
2001 3
2002 2
2004 1
2005 2
2006 2
2007 4
2008 3
2009 1
2010 2
2011 2
2012 6
2013 5
2014 8
2015 8
2016 11
2017 7
2018 1
2019 8
2020 7
2021 3
2022 8
2023 1
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F, Loesche C, Valentin MA, Jiang X, Cheng Y, Jarvis P, Peters T, Calonder C, Bruin G, Polus F, Aigner B, Lee DM, Bodenlenz M, Sinner F, Pieber TR, Patel DD. Kolbinger F, et al. Among authors: bruin g. J Allergy Clin Immunol. 2017 Mar;139(3):923-932.e8. doi: 10.1016/j.jaci.2016.06.038. Epub 2016 Aug 5. J Allergy Clin Immunol. 2017. PMID: 27502297 Free article.
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.
Sigurgeirsson B, Browning J, Tyring S, Szepietowski JC, Rivera-Díaz R, Effendy I, Keefe D, Bruin G, Paguet B, Fu R, Hampele I, Reinhardt M, Patekar M. Sigurgeirsson B, et al. Among authors: bruin g. Dermatol Ther. 2022 Mar;35(3):e15285. doi: 10.1111/dth.15285. Epub 2022 Jan 8. Dermatol Ther. 2022. PMID: 34954841 Clinical Trial.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Augustin M, et al. Among authors: bruin g. Br J Dermatol. 2022 Jun;186(6):942-954. doi: 10.1111/bjd.20971. Epub 2022 Apr 8. Br J Dermatol. 2022. PMID: 34981829 Clinical Trial.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group. Hueber W, et al. Among authors: bruin g. Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17. Gut. 2012. PMID: 22595313 Free PMC article. Clinical Trial.
Integrated chip-based capillary electrophoresis.
Effenhauser CS, Bruin GJ, Paulus A. Effenhauser CS, et al. Among authors: bruin gj. Electrophoresis. 1997 Nov;18(12-13):2203-13. doi: 10.1002/elps.1150181211. Electrophoresis. 1997. PMID: 9456035 Review.
Discovery of quinoline-based irreversible BTK inhibitors.
de Bruin G, Demont D, de Zwart E, Verkaik S, Hoogenboom N, van de Kar B, van Lith B, Emmelot-van Hoek M, Gulrajani M, Covey T, Kaptein A, Barf T. de Bruin G, et al. Bioorg Med Chem Lett. 2020 Jul 15;30(14):127261. doi: 10.1016/j.bmcl.2020.127261. Epub 2020 May 13. Bioorg Med Chem Lett. 2020. PMID: 32527559
Rasch Analysis of the Proactive Personality Scale.
Teye-Kwadjo E, de Bruin GP. Teye-Kwadjo E, et al. Among authors: de bruin gp. Psychol Rep. 2022 Oct;125(5):2788-2806. doi: 10.1177/00332941211028110. Epub 2021 Jun 29. Psychol Rep. 2022. PMID: 34187235
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Woyach JA, Jones D, Jurczak W, Robak T Prof, Illes A, Kater AP, Ghia P, Byrd JC, Seymour JF, Long S, Mohamed N, Benrashid S, Lai TH, De Jesus G, Lai R, de Bruin G, Rule S, Munugalavadla V. Woyach JA, et al. Among authors: de bruin g. Blood. 2024 May 16:blood.2023023659. doi: 10.1182/blood.2023023659. Online ahead of print. Blood. 2024. PMID: 38754046 Free article.
Reply.
Buckley N, Bruin G. Buckley N, et al. Among authors: bruin g. Can J Anaesth. 1998 Jan;45(1):93. doi: 10.1007/BF03012004. Can J Anaesth. 1998. PMID: 27519040 No abstract available.
Proteasome inhibitors with photocontrolled activity.
Hansen MJ, Velema WA, de Bruin G, Overkleeft HS, Szymanski W, Feringa BL. Hansen MJ, et al. Among authors: de bruin g. Chembiochem. 2014 Sep 22;15(14):2053-7. doi: 10.1002/cbic.201402237. Epub 2014 Aug 14. Chembiochem. 2014. PMID: 25125335
130 results